Publication date: Jun 28, 2025
In the 12-week Phase 3 KINECT-HD clinical trial, INGREZZA demonstrated a significant reduction in chorea severity, as measured by the Unified Huntingtons Disease Rating Scale Total Maximal Chorea score. At maintenance, INGREZZA demonstrated numerically larger reductions compared with placebo across all 18 cognition items and 32 of the 33 motor items. Mean changes from baseline were evaluated at maintenance across individual items from five HD-HI domains: cognition, mobility/ambulation, abnormal movements, hand/arm function and gastrointestinal health. Outcomes were assessed among affected participants, defined as those with a baseline score of at least 2 on a given item. These analyses will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress hosted by the Parkinson & Movement Disorder Alliance in Washington, D. C. Reductions in scores indicate improvement.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Movement Disorder |
| disease | MESH | cognitive decline |
| disease | MESH | memory loss |
| disease | MESH | abnormal movements |
| disease | MESH | chorea |